您的浏览器禁用了JavaScript(一种计算机语言,用以实现您与网页的交互),请解除该禁用,或者联系我们。 [武汉友芝友生物制药股份有限公司]:2025年度报告 - 发现报告

2025年度报告

报告封面

2025 279111224345477808586888991 釋義 公司資料 666 Zhou Pengfei2025625 16 2025625 33191915 H 183171712–1716 20256 252025123120256252025918202591820251231 公司資料 Zhou Pengfei •8835 39 Zhou Pengfei 1T532 2496 488 www.yzybio.com 548550552556 13381 董事長致辭 2025 20102025 2025M701II2025ESMOIIEHO20261M701FDAINDY225INDY232 202569•2025TOP10 20252VP 2025 2026AI M701Y232+M701AI 2026 Zhou Pengfei 財務摘要 2010(BsAb)Y-BODY®Check-BodyNano-Ybody® (MA)(MPE)BsAbTBsAbM701(TME)BsAbY101DY332M701Y101DM701EpCAMTCD3BsAbM701MAMPEY101DPD-L1TGF-βBsAb 管理層討論與分析 (1)M701(2)Y400CMSR&D(3) MonoComboEpCAMCD33PD-L11TGF-β—βVEGFANG2—2wAMDDME M701 M701BsAbEpCAMTCD3M701MAMPE 202410M7012024107 20253M701 20254M701 •MA:M701MAIIIM701MAPre-BLA 20257M701MAIII312 20263M701MAIII •MPE:M701MPEIb/IIIb24IbM701NSCLCMPE 20259M701MPEII100%92 202510M701MPEII2025ESMO 20262M701MPEIb/IIFDAIND 2026320251122EDCIIPuFSM701(ASCO) 2026 M701MAIIIMPEII Y101D Y101DPD-L1TGF-βBsAbY101D1PD–1PD-L1TGF-β20249Y101DI •Y101DIb/II202511CSRBiomarker 管理層討論與分析 Y332 Y332VEGFTGF-βBsAbY332VEGFTGF-β202310Y332I 20252Y332I18 Y332 Y400 Y400Y400CMS R&DY4001VEGFA/ANG2VEGFAANG2VEGFY400IIY400III23 Y225 Y225EmicizumabY225500LGMP500L 202510Y225 202512IND20251224 Y232 Y232TL1AXBsAb 18A.08(3)M701Y101DY332Y225Y232Y400 CMO/CDMO 1,4005002005020–24M701Y332202512Y22536 CMO/CDMOM701Y225CMO/CDMO M701 2026M701BD(i)M701(ii)M701(iii)Y232(iv) BD+ 管理層討論與分析 (i)(ii)(iii) 20251231M7014.082.84.020242025 2025123162.825.062.8CT20241020242024102024122025 (i)(ii)(iii) 11.110.51.21.8 (i)(ii)(iii) 管理層討論與分析 0.021.9(i)0.05(ii)20251.9202420231.72024–20252025 (i)(ii)(iii)(iv)(v)CROSMOCMO/CDMO (i)(ii)(iii)(iv)(v)(vi) 5.04.10.90.9 管理層討論與分析 84.797.612.9(i)41.0(ii)33.4(iii)86.8 2025123120241231126.3100.1 20251231131.9100.125.63.03.320251231200.5100.045.139.515.50.20.3 21.6100.784.7(i)65.2(ii)1.2(iii)3.8(iv)5.0(i)5.1(ii)4.4(iii)2.9 0.14.70.90.8 4.733.079.979.3 20251231 20251231127.568.559.020251231162.5 202512310.3202412310.5 100%20251231 管理層討論與分析 1231 20251231 202512314.50.4 — 2026123202625 202612336,880,000 H 20262 468,010,299H H20263302026330 Zhou Pengfei592014102018320229202211 Zhou35Zhou2005520061Schering-Plough Corporation201072008920106KY(6554)20117201732012120224 Zhou1989619946200511 Zhou201812201810 董事、監事及高級管理層 442024102025625 2023124302492015420111020177201342015320088201332003920087 2003720139EMBA200911 592010720221120107201812010720183 1995101999112002320117 1990620079202312 5620107202211 199271998820003202242002420106200762014720117 199261997122007720141220236EMBA 5120201202211 199910200122001320053200542009620097201222012320148201492015610932015720201220197202012 19997 董事、監事及高級管理層 4120229202211 20127201510201511201792017102019920191020253 2006620127 4220229202211 2007720114201152016520165201942019820198201911202311 2007620181020199 59202211112023925 3019947 19896199462002120014201212 董事、監事及高級管理層 41202211112023925 1520136Abax Global Capital (HongKong) Limited2020520256 2008112011 46202211112023925 2009520124201792022920229 2004620097201311A202412 64202211112023925 1990719981199812006820069201852018620238 198212198771990620022 5320256 1996119978199782001620017200312003220068200682009122010120132201322018122019120243202432025120252 (EMBA) 董事、監事及高級管理層 4820163 200632010320121 1999620095 3720215 2014420156201562016920169202032020420221 2011620147 43202512 1520142018201820233551 20042014 372023102011720254 20204202012 20116 Zhou Pengfei—— 4420216 CMC102008720215 200362008720206 462020720235 2014320207 2001620041220138 董事、監事及高級管理層 20218202211202011320114201512016120218 2001620047200292008112019920207 20236252023925Vistra Group12 20117(HKCGI)(CGI) 20251231 • • C1 企業管治報告 202512 31 C3C3 2025123120251231 20251231 Zhou Pengfei2025625 2025625 ZhouPengfei201863020201026202362 1231 企業管治報告 (1)(2)2025625(3)2025625(4)2025123134(5)2025123122(6)2025123130(7)2025123110 C.2.1Zhou PengfeiZhouPengfei 企業管治報告 20251231 3.13 20251231 20251231 20251231 20251231 Zhou PengfeiA/B2025625A/B 2025625 A:B: 企業管治報告 2025123120251231(i)2025630(ii)20251231(iii)20251231(iv) 1231 202512312024H E.1.520251231 1,000,0001,000,0011,500,0001,500,0012,000,0002,000,0012,500,0002,500,0013,000,000 Zhou Pengfei 企業管治報告 20251231 1. 110 4. 企業管治報告 (1)(2)(3)(4) (1)(2)(3) •••18••• 20251231 企業管治報告 A.2.120251231 ••• 20251231 20251231 企業管治報告 20251231 ——— ESG Vistra Group 3.2915 10% 10%9010% 1% 21152115 66633191915info@yzybio.com 企業管治報告 (a) (a)(b)(c)(d)(e)(f)(www.hkex.com.hk) (b) (c) https://www.yzybio.com/investor-relations/corporate-governance (d) (1)(2).(3)(4)(5) (e) H 66633191915 (f) (g) 企業管治報告 202562025530 2010782022113H2023925 (BsAb) 5 8590 • •M701MAMPEMAMPEM701MAMPE 董事報告 •BsAbBsAbBsAbBsAbBsAbBsAb • • • • • 2025 202512311068323 董事報告 17 2024H2024H2024H 28,413,118H2025123114.66% 13.51B(1) 15.9%42.1% 5% 5% 2024H 12 董事報告 20